Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

Summary

The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Eligibility

Inclusion criteria: Participants will be eligible for participation if all of the following are true.

* Resident of Manitoba
* Age, 6 - 24 years
* Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)
* Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram \[Celexa\], Escitalopram \[Cipralex\], Fluoxetine \[Prozac\], Fluvoxamine \[Luvox\], Sertraline \[Zoloft\], Paroxetine \[Paxil/Plaxil CR\]) therapy
* \[Cases Only\] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug
* \[Controls Only\] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks

Exclusion criteria: Participants will be excluded from participation if any of the following are true.

* Inability of parent/legal guardian/mature minors to give informed consent
* Inability of the child (6 - 13 years) to give informed assent
* Unwillingness of the child to provide a saliva sample for genetic analysis
* Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder
* History of liver or bone marrow (hematopoietic cell) transplant.

Conditions8

Browse More Trials